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ABSTRACT
LARP1 is an oncogenic RNA-binding protein required for ribosome biogenesis and cancer cell survival.
From published in vitro studies, there is disparity over which of two different LARP1 protein isoforms
(termed the long LI-LARP1 and short SI-LARP1) is the canonical. Here, after conducting a series of
biochemical and cellular assays, we conclude that LI-LARP1 (NM_033551.3 > NP_056130.2) is the
dominantly expressed form. We observe that SI-LARP1 (NM_015315.5> NP_056130.2) is epigenetically
repressed and that this repression is evolutionarily conserved in all but a small subclade of mammalian
species. As with other LARP family members, there are multiple potential LARP1 mRNA isoforms that
appear to be censored within the nucleus. The capacity of the cell to modulate splicing and expression
of these apparently ‘redundant’ mRNAs hints at contextually specific mechanisms of LARP1 expression.
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Introduction
The La-related proteins (LARP) are an evolutionarily conserved
family of RNA-binding proteins (comprised of LARP 1, 1B, 3,
4A, 4B, 6 and 7) linked to cancer [1]. LARP1 is oncogenic with
higher tumour levels of LARP1 protein corresponding with
adverse prognosis in ovarian, colorectal and prostate cancer
[2–4]. LARP1 is believed to bind mRNA at two sites; via its
conserved La module, an RNA-binding region comprised a La
domain and an adjacent RNA recognition motif (RRM) and via
its C terminal ‘DM15 domain’ [5]. LARP1 is complexed with
poly-A binding protein (PABP) and binds an interactome of
over 3000mRNAs including 5ʹTOP-motif containing transcripts
which are known to encode the ribosomal machinery [3]. As it
has been shown to be phospho-regulated by mTORC1, LARP1
has thus been identified as the functional link between mTOR
signalling and ribosome biogenesis [6].
It has been estimated that the human genome contains
only 19,000–21,000 protein-coding genes but more than
70,000 proteins are synthesized [7]. This is explained by the
alternative processing of pre-messenger RNA to create multi-
ple mature mRNA transcripts; thus a single gene has the
potential to encode many protein isoforms. This mechanism
increases proteome complexity [8]. However, despite genes
encoding multiple mRNA transcripts, often only one protein
is dominantly expressed [9] indicating a process of selection
or ‘censoring’ of mRNA that are successfully processed and
released into the cytoplasm [10].
The gene encoding human LARP1 is located at chromosome 5
(5q33.2) with at least nine known curated putativemRNA isoforms
(https://www.ncbi.nlm.nih.gov/gene). Those isoforms are pre-
dicted to encode proteins ranging in size from 824 to 1096 amino
acids (Fig. 1A). The ‘canonical’ LARP1 is listed on the TheNational
Center for Biotechnology Information (NCBI) website as transcript
variant 1 (NM_015315.5) encoding a protein of 1019 amino acids
(NP_056130.2) known here as the ‘short isoform of LARP1’ (SI-
LARP1). This is often used as the definitive LARP1 for studies of its
function [6,11,12]. A second transcript variant 2 (NM_033551.3) is
cited by UniProtKB as being the canonical form of LARP1 [1,2,13]
and corresponds to a 1096 amino acid protein (NP_291029.2)
referred to here as the ‘long isoform of LARP1’ (LI-LARP1). Each
of these two LARP1 isoforms is transcribed from different promo-
ter sites and has a unique transcription start site (TSS) resulting in
a different exon 1 sequence whilst the remaining exons (exons
2–19) are identical. The resulting SI-LARP1 protein differs from
LI-LARP1 by lacking the first 77 amino acids and with different
amino acids M1 to N67.
Western blotting using antibodies raised to various regions
of LARP1 generates a duplex band of approximately 150/
130kDa, which has been interpreted as representing both
LARP1 isoforms [12]. To explore this, we systematically con-
ducted a series of in silico, transcriptomic, biochemical and
cellular assays to elucidate the true expression profile of
LARP1 in cancer and normal cells.
Results
Isoform landscape of LARP1 in cancer cells
Nine different validated isoforms are listed for LARP1 in the
NCBI gene database (Fig. 1A). Among those, the ‘canonical’
LARP1 is listed as transcript variant 1 (NM_015315.5) encod-
ing a protein of 1019 amino acids (NP_056130.2) known here
as the ‘SI-LARP1’ (Fig. 1B). To investigate the expression
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profile of LARP1 in cells we used publicly available RNA
sequencing datasets (Fig. 2A). We extracted 371 submitted
biosamples containing poly-(A) RNA sequencing data sets
from 198 tissues, 128 cell lines and 54 primary cells and
mapped their reads to the chromosome region hg38:Chr5
154 700 000 to 154 850 000 containing all predicted LARP1
isoforms [14]. First, we focused on sequencing reads mapping
to the first exon, which is distinct for both LARP1 isoforms.
We found that the available sequencing data exclusively
mapped to exon 1 of the long LARP1 isoform, with no
reads mapping to exon 1 of SI-LARP1. Exons 2–19, which
are shared between the two isoforms, were fully covered by
the available sequencing data.
To gain further insights into the expression of LARP1
isoforms we conducted Oxford Nanopore sequencing
technology (ONT) in HEK-293 T and OVCAR-8 cells,
immortalized human embryonic kidney and ovarian cancer
cell lines, respectively (Fig. 2B-D). This direct RNA sequen-
cing technique allows the detection of long read transcripts
isoforms and allows the quantification of transcript abun-
dance without PCR bias [15]. ONT reads were mapped to
human genome (Hg38) and aligned reads were visualized
using the integrated genome viewer (IGV). In HEK-293 T
cells, we detected a total of 2,038,842 transcripts while only
1,834,870 transcripts were detected in samples from OVCAR-
8 cells. First, we quantitated all transcripts mapping to the
seven LARP family members and normalized the reads to the
total amount of detected long read transcripts (transcripts
per million TPM) (Fig. 2B). We observed that, of the LARP
family members, LARP3 has the highest number of transcripts
Figure 1. Isoforms of LARP1.
A) Table of all reported LARP1 isoforms on NCBI (stand 04.11.2019). B) Representative illustration of the exon organization of ‘short’ and ”long” LARP1 isoforms and
respective translated proteins. Both isoforms differ in nucleotide/amino acid sequence and length of exon 1 (red). Black squares represent exons. Line represents
untranslated regions (UTR). La-module (LAM), RNA recognition motif L5 (RRM-L5) and LARP1 specific DM15 domain are given in orange. C) In silico analysis of
expression levels of short and long LARP1 isoforms indicates a prevalent expression of the long isoform in primary cells, tissue and cancer cell lines. Data extracted
from ENCODE database and visualized using UCSC Genome browser [23,44]. Also see Supporting Data 1 for a full list of analyzed data
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at 194 TPM. In contrast, the other LARPs showed values well
below 50 TPM with the expression of LARP1B and LARP4B
being lowest. Interestingly, LARP1 shows a higher expression
level in cancerous OVCAR-8 (52TPM) cells than in HEK-
293 T cells (38TPM) in agreement with previous studies [4].
To analyze the expression of LARP1 isoforms in these cells,
we visualized the splice junctions using Sashima plots (Fig.
2C). Using this direct sequencing approach, SI-LARP1 was
undetectable in the two tested cells lines. Although expression
of the LARPs was low compared to other genes e.g. GAPDH
(up to 6396 TPM in OVCAR-8 cells)(Supporting Data 2), we
clearly could identify LI-LARP1 as the predominantly
expressed LARP1 isoform. Interestingly, we also observed an
accumulation of 5ʹ truncated LARP1 transcripts. Of note co-
expression of alternative isoforms was detected for LARP1B
(NM-018078 NM_178043 NM-032239) and LARP6
(NM_197958, NM_018357) (Fig. 2D). For the other LARPs,
we were able to confirm that the major transcript detected by
Figure 2. Transcriptomic profile of LARP1 isoform expression.
A) In silico analysis of expression levels of short and long LARP1 isoforms indicates a prevalent expression of the long isoform in primary cells, tissue and cancer cell
lines. Data extracted from ENCODE database and visualized using UCSC Genome browser. Also, see Supporting Data 1 for a full list of analyzed data. B) Quantification
of transcripts after direct RNA sequencing of OVCAR-8 and HEK-293 T cells by Nanopore Sequencing. C) Splice site selection of LARP1, D) LARP1B and LARP6 in
OVCAR-8 and HEK-293 T cells. Sashimi plots are shown for most frequent splice site selections. A detection cut off of minimum of 2 exon-exon junction coverage was
applied. The most frequently detected transcript variants are shown below the plot including the NCBI accession number. Also see Supporting Data 2.
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ONT sequencing corresponded with the canonical isoform
(Supporting Data 2).
To validate our ONT sequencing findings that LI-LARP1 is the
dominant isoform, we designed two pairs of specific primers to
detect either the short or long LARP1 isoforms or both forms
(referred to here as ‘total LARP1’) by PCR (Fig. 3). Forward
primers corresponding to exon 1 of each LARP1 isoform and
reverse primers to the exon junctions of downstream exons were
designed. Functionality of these primers was confirmed by
successful amplification following expression of recombinant SI-
LARP1 or LI-LARP1. Primers for detecting total LARP1 were
designed to anneal in exon 7, common to all predicted isoforms.
We detected the expression of LI-LARP1 in 501-MEL and
OVCAR-8 cells but we could not detect a PCR amplification
product for SI-LARP1 (Fig. 3A).All PCRproductswere sequenced
to validate the desired amplicon (data not shown). Next, we
designed primers specific to the open reading frame of the long
LARP1 isoform and amplified it by PCR from a cDNA library.
Figure 3. Analyzes of the mRNA expression of the short and long isoform in human cells.
A) PCR amplification of ”short” and ‘long’ LARP1 isoforms using specific primers hybridizing to exon 1 of the respective isoform. S1/S2 and L1/L2 stand for primer
pairs detecting SI- or LI-LARP1, respectively. T stands for total RNA detected using a primer pair annealing to constitutively expressed Exon 7. HK stands for
housekeeping gene OAZ1. B) PCR product containing the complete open reading frame of long LARP1 was generated using gene-specific primers annealing to 5ʹ-
and 3ʹ- end of the open reading frame. Amplification products were purified and sequenced. Junction of ‘long’ LARP1 specific exon 1 and common exon 2 is given in
chromatograms. C) Systematic analysis of mRNA expression levels of short and long LARP1 isoforms in NCI-60 cancer panel using quantitative PCR. Specific primers
for short and long LARP1 were used. Results of one representative primer pair for each isoform are shown. Dark and light-coloured bars represent proportion of SI- or
LI-LARP1 expression, respectively. D) Expression of LI-LARP1 and absence of SI-LARP1 mRNA was validated in SK-OV-3, OVCAR-8, MCF-7, and 501-MEL cells using
quantitative PCR. Resulting data were normalized against OAZ1. (E) Quantitative PCR analysis of expression of short LARP1 using random or oligo-(dT) primers for
reverse transcription suggest that mRNA is missing poly-(A) tail. All qPCR data were normalized against OAZ1 and relative expression values were calculated using
2-Δct method.
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Sequencing of the PCR product revealed the full predicted nucleo-
tide sequence for LI-LARP1 including its specific exon 1 (Fig. 3B).
Of note, all attempts to amplify the coding sequence of the SI-
LARP1 isoform failed, indicating that this isoform did not exist in
our cDNA library.
Long LARP1 isoform is dominantly expressed in NCI-60
cancer panel
To determine whether LI-LARP1 is expressed in a wider panel of
cancer cell lines, we investigated the expression levels of LI-
LARP1 and SI-LARP1 across the NCI-60 cancer cell panel [16]
containing a selection of melanoma, renal, ovarian, brain, leu-
kaemia, breast, non-small cell lung and prostate cancer cell lines
(Fig. 3C). Although there was an up to 37-fold variation in
expression of LI-LARP1 between the samples, it was detectable
in all cell lines. However, mRNA expression of SI-LARP1 was
below the threshold of detection in all lines (cT values <35). We
validated these findings by measuring SI and LI-LARP1 in cell
lines from the NCI panel (MCF-7, OVCAR-8, SK-OV-3, 501-
MEL and HEK-293 T)(Fig. 3D). In all five cell lines, levels of LI-
LARP1 were at least 1000 fold higher than of the SI-LARP1.
Since expression levels of SI-LARP1 were close or below the
detection limits, we explored whether the remaining detected
transcripts were artefacts. A hallmark of mature mRNA is the
existence of a 3ʹ poly-(A) tail, which is required for its nuclear
export [17]. Polyadenylated total mRNAs, extracted from
OVCAR-8, SK-OV-3, 501-MEL and HEK-293 T, were reverse
transcribed using either random or oligo-(dT) primers (Fig. 3E).
As random primers anneal to any type of transcript within the
RNA pool, PCR amplification will detect also non-processed
mRNA species. In contrast, oligo-(dT) primers lead to
a specific reverse transcription of polyadenylated mRNAs.
Levels of SI- and LI-LARP1 isoform in both cDNA libraries
were measured using gene-specific primers. Expression levels
were normalized against OAZ1 and relative mRNA expression
was calculated. We found that levels of fully processed and
polyadenylated SI-LARP1 mRNA were below detection limits
suggesting the SI-LARP1 mRNA is expressed but not fully
processed to mature, polyadenylated mRNA.
Altogether, our data indicate that the mRNA for the long
LARP1 isoform is the dominantly expressed form in wide range
of cancer and normal cells and that the SI-LARP1 mRNA, if
expressed, is present at low levels and in an immature form.
Identification of peptides specific for long isoform in four
different human cell lines
As described previously, SI- and LI-LARP1 have distinct
N-termini encoded by different exon 1 sequences (Fig. 4A). Both
exons end in-frame, thus the exon selection does not affect the
downstream reading frame and amino acid composition of
LARP1. The long isoform constitutes a 77 amino acid longer
polypeptide chain and leads to protein predicted to be 8.4 kDa
larger. When both forms are exogenously expressed only a small
difference in the migration pattern on an SDS-Gel was observed
(Fig. 4B). Comparing the migration patterns of exogenously
expressed SI- and LI-LARP1 with endogenous LARP1 showed
the latter co-migrates with LI-LARP1 indicating that the protein
product of LI-LARP1 is dominantly expressed. To validate this, we
followed a two-step strategy; first we ectopically expressed both
LARP1 isoforms in OVCAR-8 cells and enriched the LARP1
protein by immune-precipitation from crude protein lysate using
antibodies against the co-expressed Xpress tag (Fig. 4C and
Supporting Data 3). Subsequently, samples were subjected to in
solution-digestion using Trypsin or Chymotrypsin. Shotgun LC-
MS/MS analyses was performed to identify isoform-specific pep-
tides mapping to the N-terminus of either the SI-or LI-LARP1
isoform (Supporting Data 4). We identified three peptides gener-
ated from the sequence position at 45 and 46 (with masses of N46
SVALAAAPR: 485.2773Th (m/z); K45NpSVALAAAPR: 549.3257
Th (m/z); K45NSAVALAAAPR: 589,3085 Th (m/z)) as unique to
the SI-LARP1 (Fig. 4D). In contrast, for the LI-LARP1 we identi-
fied 152 peptides generated from the protein sequence corre-
sponding to exon 1 (Supporting Data 4). In a second step,
endogenous LARP1 from OVCAR-8, 501-MEL, SK-OV-3 and
HEK-293 T cells was immuno-precipitated and subjected to
mass spectrometry to detect pre-specified isoform-specific pep-
tides using a supervised and automated algorithm (Fig. 4E-F). The
peptide coverage for LARP1 ranged from 24-44% for the endo-
genous immunoprecipitated protein. Although unique peptides
corresponding to LI-LARP1N-terminus were identified in all four
cell lines, we could not identify any peptides specific to SI-LARP1
isoform in any of the samples. These results are consistent with the
observed absence of mRNA corresponding to the SI-LARP1.
Promoter of short isoform is hypermethylated which
suppresses its promoter activity
Next, we investigated the mechanism by which expression of the
SI-LARP1 is regulated. Transcriptional activity correlates with
chromatin state, which is characterized by histonemodifications,
open chromatin and specific transcription factor binding [18].
Therefore, we used three publicly available datasets to predict the
promoter activity of the short and long LARP1 isoforms (Fig.
5A). The predicted TSS of the SI-LARP1 is located at GRCh38.
p13:154,712,843 while the TSS of the LI-LARP1 is within the first
intron of the SI-LARP1 at position GRCh38.p13:154,755,377.
We judged the transcriptional activity based on three para-
meters. First, we used ChIP-seq data to identify H3K27ac
marks, which represents acetylation of lysine 27 of H3 histone
protein leading to transcription enhancement [19]. Second, we
used data from human methylation arrays to identify CpG
methylation, which correlates with silencing of genes and, con-
versely, their demethylation stimulates gene expression [20,21].
Third, we predicted the chromatin state segmentation for nine
human cell lines by computationally integrating ChIP-seq data
using a multivariate Hidden Markov Model (HMM) [22]. All
data were aligned to GRCh37/hg19 and analyzed using the
UCSC genome browser (Fig. 5A) [23]. We found high levels of
CpG methylation but low H3K27AC marks within the SI-
LARP1 TSS suggesting diminished promoter activity. In con-
trast, the LI-LARP1 TSS had low levels of CpG methylation and
high H3K27AC marks suggesting an active promoter site. Of
note for SI-LARP1, the only significant increase in promoter
activity was observed in human embryonic stem cells. Altogether
our data indicate that the promoter region of LI-LARP1 is in an
open chromatin state, suggesting a high promoter activity for
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Figure 4. Identification of peptides specific for long isoform in four different human cell lines.
A) A sequence alignment of N-terminal protein sequence of SI-and LI-LARP1 protein. B) Detection of endogenous and recombinantly expressed SI- and LI-LARP1
protein using antibody raised against peptide common to both isoforms. For expression constructs see Supporting Data 3. C) To identify the peptides corresponding
to LARP1, we immunoprecipitated endogenous and overexpressed SI- and LI-LARP1 isoform using either LARP1 or Xpress tag specific antibodies. Detection of total
ERK2 served as loading control. D) Immunoprecipitated samples were subjected to in solution tryptic or chemotryptic digestion and mass spectrometric analysis were
performed. Resulting peptides were mapped to either long or short LARP1 protein sequence (grey shadow). Mass spectrometry identified peptides mapping
specifically to short or long LARP1 isoform, when ectopically expressed (red square). MS/MS Spectra, m/z and retention time (RT) for peptides specific to SI- or LI-
LARP1 are given. E) Control western blots of LARP1 pull downs using specific antibodies against LARP1. IgG control is shown. F) Summary table from peptide
identification specific to LARP1 by mass spectrometry from recombinant and endogenous LARP1. Number of identified peptides specific for SI-or LI-LARP1 are given.
Total number of peptides and peptide coverage for SI-(*) and LI-LARP1 ($) is given.
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this region while the promoter of the SI-LARP is epigenetically
repressed.
To confirm the repression of the SI-LARP1 promoter by
CpG methylation, we sought to re-activate its expression by
demethylation (Fig. 5B) using 5ʹ Azacitidine (5-Aza),
a chemical analogue of cytidine and an inhibitor of DNA
methyltransferase [24]. To do so, SK-OV-3, OVCAR-8, 501-
MEL and HEK-293 T cells were treated with an increasing
concentration of 5-Aza for 3 or 5 days. To confirm the re-
activation of expression of SI-LARP1, we measured the levels
Figure 5. Promoter of long isoform is demethylated and activated while promoter of short isoform is methylated and inactive.
A) In silico analysis of H3K27AC marks, CpG methylation and promoter activity of SI- and LI-LARP1. CpG Methylation is indicated by a heatmap. Red represents the
highest and blue for the lowest methylation. Short isoform promoter activity is predicted to be a weak enhancer (yellow) while the region around the long isoform
promoter comprises an active promotor (red) with strong enhancer elements and transcriptional transition and elongation sites. B) Quantitative PCR analysis of SI-
LARP1 of 5ʹ Azacytidine treated cells at different concentration over 3 days or fixed concentration at different timepoints, using random primers for reverse
transcription were performed. C) In silico analysis of the conservation of exon 1 of the short and long LARP1 within vertebrates. Conservation is calculated by Phylop
or Phastcons and represented as blue or green peaks, respectively. Multiple sequence alignment is shown from representative organisms of the vertebrate
subphylum (mammals, amphibians, reptile, fish and bird). The mammalian subdivision placentalia is highlighted with a bracket (*). Location of exon 1 of short and
long isoform is indicated by red frame. Pairwise alignments of each species to the human genome are displayed and nucleotide conservation is indicated by green
bars. Data have been extracted from UCSC genome browser [23].
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of SI-LARP1 mRNA in treated and control cells by quantita-
tive PCR (Fig. 5B) and observed up to fivefold concentration-
dependent increase in SI-LARP1 after 3 days. When we used
an optimized concentration and increased the incubation time
up to 5 days, we found a 20-fold increase of SI-LARP1 mRNA
in OVCAR-8. However, we did not detect any protein corre-
sponding to the SI-LARP1 by western blotting (Supporting
Data 5B). Of note, we did not observe a significant increase in
LI-LARP1 mRNA nor protein expression (Supporting Data
5A-B). These data indicate that expression of SI-LARP1 is to
some extent epigenetically regulated. However, even when
epigenetically de-repressed, SI-LARP1 is not synthesized into
protein by the cytoplasmic translation machinery.
Next, we explored whether the expression pattern of LI-
LARP1 is similar to that of both SI-LARP1 and endogenous
LARP1. Previous work by Hopkins et al. showed that transient
knowdown of LARP1 using siRNA targeting both SI-LARP1 and
LI-LARP1 in OVCAR-8 and SK-OV-3 cells was associated with
a decrease in cell viability and increase apoptosis[4]. To validate
that this observation is attributable to LI-LARP1, we targeted
mRNA of LI-LARP1 with specific siRNAs to unique exon 1 or
the ubiquitous exon 13 (Supporting Data 5 C). Both siRNAs
caused a reduction in cell viability when compared to OVCAR-8
cells treated with scramble siRNA (Supporting Data 5 C).
Interestingly, the lower protein band (that measures approxi-
mately 130 kDa) in the LARP1 western blot duplex is success-
fully depleted using siRNA against exons 13, but not using
siRNA against its N-terminal exons (Supporting Data 5C).
This indicates the band corresponds to an unknown
N-terminally truncated variant of LARP1.
Furthermore, it is well established that LARP1 interacts
with PABP to bring the 5ʹ and 3ʹ UTR of the target mRNA
in close vicinity [25,26]. To prove this was true for LI-LARP1,
we pulled down endogenous and ectopically expressed LARP1
and found that both SI-LARP1 and LI-LARP1 were able to
bind PABP (Supporting Data 5D).
Next, we were interested whether SI-LARP1 could have
a distinct functional role. To investigate this, we analyzed the
level of conservation of TSS of both LARP1 isoforms (Fig. 5C).
We hypothesized that evolutionary conservation would hint
towards a selective pressure and consequently a different role
for each isoform. To decipher the evolutionary conservation of
the LARP1 isoforms we generated a multiple sequence align-
ment of the 100 available LARP1 sequences in subphylum of
vertebrates (Birds, Fish, Amphibia, Reptiles, Mammals) using
UCSC genome browser [23]. Surprisingly, we found a strong
conservation of exon 1 of LI-LARP1 through the whole subphy-
lum but conservation of SI-LARP1 exon 1 was only present in
the Placentalia subdivision, which includes humans and other
primates. This indicates it may have acquired a functional role
late in evolution, specific to placental mammals. By contrast, the
conservation of LI-LARP1 indicates a far more ancient role
across multiple clades.
Discussion
Although LARP1 is a known post-transcriptional regulator, its
dominant isoform has been disputed. We show here that
mRNA and protein corresponding to the long isoform (or LI-
LARP1) is ubiquitously expressed in cancer and non-cancer
cells. In contrast, transcripts encoding SI-LARP1 could be
only detected when the promoter was demethylated suggest-
ing it is, to some extent, epigenetically regulated. However, we
were unable to detect a protein product following epigenetic
derepression, indicating a more sophisticated post-
transcriptional regulation [27]. Importantly, we show that
the lower band of the 150/130 kDa duplex commonly
observed in western blots of endogenous LARP1 (and attrib-
uted to its long and short isoforms) [4,12] infact does not
represent a protein product of SI-LARP1. However, the 130
kDa band appears to be an N-terminally truncated variant of
LARP1 rather than a product of degradation. The function of
this as yet unknown LARP1 variant has yet to be determined.
Our findings support a recently published study predicting
over 10 potential alternative promoters for LARP1 [28] and are
consistent with evidence that most coding genes have multiple
isoforms but only one expressed protein [9]. Whilst the evolu-
tionary conservation of an expressed isoform indicates it has
a conserved biological function [29], the role of non-expressed
isoforms remains controversial [9,30]. While some hypothesize
they are transcriptional noise [31], others propose they are
required to regulate protein function, interactions or localization
[32] or to generate an evolutionary testing ground allowing func-
tions and domains to evolve [33,34]. Indeed, we show that exon 1
of SI-LARP1 is highly conserved within the mammalian
Placentalia subclade suggesting it provides a functional and thus
evolutionary advantage distinct from LI-LARP1. Furthermore,
detection of SI-LARP1 mRNA only in human embryonic stem
cells, may indicate a role in embryonic development. The exact
role of SI-LARP1 and subcellular localization needs to be
addressed in future research.
The first exons from SI- and LI-LARP1 map to a highly
unstructured region upstream of the La-Module that does not
contain distinct protein domains or known substrate binding
regions [13]. This is consistent with the observation that
alternative exons locate to sequences within intrinsically dis-
ordered protein regions rather than functional domains
[35,36]. As these regions are sites of post-translational mod-
ification and involved in protein–protein interactions [37–39],
it has been speculated that remodelling of intrinsically disor-
dered domains expands the cell-type or condition-specific
gene repertoire [39].
We show that variation in isoform expression is observed
in other LARP family members. Using long read RNA
sequencing, we identified several alternatively expressed iso-
forms of LARP1B and LARP6. Both express a full length and
a significantly shorter isoform. Interestingly, their expression
also seems to differ between cancer and non-cancer cell lines.
Indeed, it has been previously shown that cancer associated
splicing changes can drive tumour progression [39]. It would
be interesting to investigate whether those isoforms encode
differentially expressed proteins that fulfil distinct molecular
functions.
In general, RBPs like the LARPs are commonly recognized
as ‘cytoplasmic transcription factors’, that bind and regulate
the stability, half-life and subcellular localization of multiple
RNAs and are mobilized in response to cellular stress [40].
Using currently available sequencing tools, we show that there
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is significant censoring of LARP1 expression in favour of
a single isoform that is predominantly expressed. This pro-
vides an intriguing insight into the evolution and functional
relevance of LARP1 and the wider LARP family of proteins.
Materials and Methods
Cell culture and transfections
SK-OV-3, 501-MEL and OVCAR-8 cells were cultured in
RPMI medium with 10% (v/v) Foetal Bovine Serum (FBS)
and 1% (v/v) Pen Strep. HEK-293 T and MCF-7 cells were
cultured in DMEM with high Glucose, GlutaMAX™, 10% (v/v)
FBS and 1% (v/v) Pen Strep. For primer validation, OVCAR-8
cells were transfected with 1 μg of pCMV6 plasmid containing
the coding sequence for the short or long isoform (Supporting
Data 3) using FuGene6 transfection reagent, following manu-
facturers instructions. After 24 h incubation, the cells were
washed in PBS, harvested and RNA extracted. For LARP1
knockdown, OVCAR-8 cells were transfected with
Lipofectamine RNAiMax (ThermoFisher) and siRNAs target-
ing LARP1, either ‘Exon 13’ (AGACUCAAGCCAGACAUCA)
or ‘LI-LARP1 Exon 1’ (GUGAACCCGUGGACUAAGAAC).
Cells were trypsinized 24 h after transfection and reseeded for
proliferation assays. Cyquant NF Cell Proliferation assay
(ThermoFisher) was used to monitor the quantity of viable
cells at 24 h intervals, with values normalized against initial
readings taken after cells had adhered. Concurrently, cell lysates
were harvested 48 h after siRNA transfection for Western
blotting.
Nanopore sequencing and analysis
OVCAR-8 and HEK-293 T cells were seeded in 10 cm dish
and grown overnight to 70% confluency. Cells were washed
with PBS and RNA was extracted using Trizol [41]. Poly-(A)
RNA was captured using Oligotex mRNA mini kit (Qiagen)
according to manufactures instructions. RNA was directly
sequenced using Direct RNA sequencing kit SQK-RNA002
(Oxford Nanopore) according to manufactures instructions.
Libraries were sequenced on R9.4.1 flow cells which were run
for 8 h using live basecalling, files were outputted in Fast5 and
Fastq format. Fastq files were concatenated and processed
through the Oxford Nanopore Pinfish RNA analysis pipeline
(https://github.com/nanoporetech/pipeline-pinfish-analysis).
In brief, this pipeline aligns reads to the GRCh38 reference
genome and then identifies, polishes and collapses transcripts
into a consensus GFF file.
In silico analysis
RNA expression levels of LARP1 were analyzed using next
generation sequencing data extracted from ENCODE project
(Extraction date 27.09.2018). We downloaded 371 call sets
from the ENCODE portal [40] containing Poly-(A) RNA
sequencing data from 198 tissues, 128 cell lines and 54 primary
cells. Unique positive strand reads were mapped to either long
(XM_005268404.3) or short (NM_015315.4) isoform of LARP1
using UCSC Genome browser on Genome Reference
Consortium Human Build 38 patch release 12 (GRCh38.p12)
human GRCh38/hg38 assembly (Dec 2013) [23].
CpG methylation as determined by Illumina Infinium
Human Methylation 450 Bead Array (ENCODE project)
aligned to GRCh37/hg19 was selected to be displayed in
dense mode within the UCSC genome browser. The dataset
comprised over 63 different cell lines.
Due to absence of annotation of the long isoform of
LARP1, the genomic location was extracted from GRCH38/
hg38 XM_005268404.3 at chr5:154755575–154817605 and
NM_015315.4 at chr5:154712902–154817607 for the short
and long isoform, respectively. Genome coordinates were
converted into GRch37/hg19 genome annotation using the
LiftOver tool at UCSC browser.
Third, we predicted the chromatin state segmentation for
nine human cell lines by computationally integrating ChIP-
seq for nine-factors plus input using a multivariate Hidden
Markov Model (HMM) [22].
RNA extraction, cDNA synthesis and quantitative PCR
RNA extraction was performed according to manufacturer's
protocol of the GeneEluteTM Mammalian Total RNA
Miniprep Kit (Sigma-Aldrich, Cat. No. RTN70-1KT) and
a DNase digestion was performed to reduce genomic contam-
ination using RNase-Free DNase Set from QIAGEN.
One μg RNA was reverse transcribed using High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystem). If not
otherwise stated, random primers were used. Twenty μl of
cDNA reaction was diluted with 130 μL RNase-free water and
stored at −20°C until further use.
The quantitative polymerase chain reaction (qPCR) was car-
ried out to analyze the cDNA samples in a MicroAmpⓇ Fast 96
well plate reaction plate (Applied Biosystems) using 2x Fast
SYBR Green Master Mix (Thermo Fisher Scientific).
Quantitative PCR was performed in three technical replicates.
For the run, the StepOnePlus Real-Time PCR System (Applied
Biosystems) was used with the fast run mode (40 min) alongside
melting curve analyzis. Full length LI-LARP1 cDNA was gener-
ated using Maxima Reverse Transcriptase (Thermo Scientific)
and oligo-(dT) primers. cDNA was amplified by PCR using
Qiagen LongRange Polymerase with primers amplifying the
full length coding sequence (CDS). PCR product was purified
and cloned into a pCR4-TOPO vector following the instructions
of the TA-CloningTM kit (Invitrogen). Insert of purified plasmid
DNA was sequenced (Eurofins).
Analysis of NCI-60 cDNA library
The cDNA of the NCI-60 human cancer cell panel [16] was
kindly provided by Gareth Bond (Ludwig Institute for Cancer
Research, Oxford). A 1:20 dilution of the cDNA was per-
formed by mixing 5 μL of the cDNA sample and 95 μL
nuclease free water. The screen was performed by qPCR
analysis using the following seven primer pairs: OAZ1,
GAPDH, LARP1 long 1, LARP1 long 2, LARP1 short 1,
LARP1 short 2. Primers were selected for amplification effi-
ciency of 100% (± 10%) and specificities were validated using
melting curve analyses. Quantitative PCR analysis was
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performed using Fast SYBR Green Master Mix (Thermo
Fisher Scientific) using the fast amplification protocol accord-
ing to manufacturer's instructions. The average of three repli-
cates was normalized against either OAZ1 or GAPDH
housekeeping genes and relative mRNA abundance was cal-
culated using the 2 – Δct method [42].
Primers
Following primer pairs were used for the analysis: LARP1
short 1 CTTTGGAGGGTGCTTTTGTC, AGTGTTCAGGG
TTGCTGAAG; LARP1 short 2 CCAGAGCTGGATTTCC
AAGA, CTAAACAGCGCAAAGGCAG; LARP1 long 1 GTG
AACCCGTGGACTAGAAC, ACTGTGGCTGAACACTCT
TG; LARP1 long 2 CCCAGGAACACTCTGCTC, ACTGTGG
CTGAACACTCTTG; total LARP1 GAACCCATTTTGAC
TACCAG, TTGATGTAGTCTTTGAGGCAG; OAZ1 ATA
GTCAGAGGGATCACAATC, CGTTAGTTCCTCTGTTACA
TTC; GAPDH GTCTCCTCTGACTTCAACAGCG, ACCA
CCCTGTTGCTGTAGCCAA; CDS ATGGCCACTCAGGT
GGAGC, TCACTTTCCCAAAGTCTGTGTGTTC
Overexpression and Pull-down of short and long isoforms
of LARP1
OVCAR-8 cells were cultured in 10 cm dish and transfected with
2 µg of pcDNA 4 constructs expressing Hismax/Xpress-tagged
codon-optimized coding sequences of short (NM_015315.4.1)
and long (XM_005268404.3.1) isoforms of LARP1 using Fugene
6 transfection reagent (Promega) according to the manufac-
turer’s instructions. Forty-eight hr following transfection, cells
were lysed using ice-cold immunoprecipitation (IP) lysis buffer
(50 mM Tris HCl, pH 7.6, 150 mM NaCl, 20 mM MgCl2 and
0.5% NP-40) supplemented with EDTA-free protease and phos-
phatase inhibitors cocktail (Roche). Cell lysates were incubated
for 30 min with agitation at 4°C, followed by centrifugation at
13,000 rpm for 15 min. Resulting supernatants were then col-
lected, and protein concentration was determined using Pierce
Coomassie Plus (Bradford) Assay Reagent (Life Technologies).
For each sample, an aliquot of cell lysate (10%) was saved as
input protein and the rest was incubated with 20 µg of anti-
LARP1antibody (ab86359, Abcam) or Xpress Antibody (R910-
25, Thermo Fisher Scientific) at 4°C overnight with agitation.
70 µl of Dynabeads Protein G (Life Technologies) was added to
each IP sample and incubated at 4°C for 2 h with agitation.
Dynabeads-Ab-Ag complexes were then washed 3 times by
gentle pipetting using 100 µl of washing buffer (PBS pH 7.4,
0.02% Tween 20). LARP1 immunoprecipitates were eluted from
beads by heating samples in 1% sodium dodecyl sulphate (SDS)/
β-mercaptoethanol at 95°C for 5 min, then loaded onto
NuPAGE 3-8% Tris-acetate gels (EA0378BOX, Life
Technologies) for immunoblotting.
Mass spectrometry
In-solution digest, SDS containing samples were precipitated
with Chloroform/Methanol twice [43] after dilution up to
a volume of 175μl and reduction/alkylation with DTT and
Iodoacetamide. Protein pellets were re-suspended in 100μl
6 M Urea, diluted with 500μl water before digest with 0.6μg
Trypsin or Elastase over night. Samples were acidified and
desalted using SOLA cartridges (Thermo Pierce).
Peptides were injected into a nano LC-MS/MS platform con-
sisting of a Dionex Ultimate 3000 UPLC and an Orbitrap Fusion
Lumos mass spectrometer. Peptides were separated on a 50 cm
nEASY Spray column (ES803A) with a gradient from 5-35%
Acetonitrile in 5%DMSO/0.1% formic acid over 60 min. MS-
spectra were acquired at a mass resolution of 120000 and
an AGC target of 400000. Precursors were isolated with a mass
window of 1.6Th and fragmented by HCD. Peptide fragments
were analysed in the Orbitrap at 30000 resolution and an AGC
target of 50000 for up to 54 ms. Collision energy was set to 30%.
Precursors were acquired with the top speed methods and a 3 s
cycle time and then excluded from repeated selection for 7 s.
MS/MS data were analysed with PEAKS 8 (Bioinformatics
Solutions). Mass tolerances were set to 5ppm (precursor) and
0.03 Da (fragment). Carbamidomethyl (Cys) was set as fixed
modification and Oxidation (M), Deamidation (Asn, Gln) and
Phosphorylation (Ser, Thr, Tyr) were set as variable modifica-
tions. The used database (Uniprot reviewed, Homo sapiens,
retrieved 26/06/2018) was supplemented with known LARP1
isoforms (see Fig. 1). Peptide FDR was adjusted to 1%.
Extracted ion chromatograms of isoform-specific LARP1 pep-
tides were generated with Freestyle (Thermo).
Genome-wide demethylation
The demethylation of the genome was carried out by
a 5-Azacytidine treatment of the following four cell lines: SK-
OV-3, 501-MEL, OVCAR-8 and HEK-293 T cells. Briefly, cells
have been cultivated in a 10 cm cell culture dishes to 70%
confluency. Indicated concentration of 5-Azacytidine
(ab142744, Abcam) was added to the cells and medium was
replaced daily. Control cells were treated with a respective
volume of DMSO. Cells were harvested after 3 and 5 days,
washed with PBS and total RNA was extracted. Messenger
RNA expression was analyzed by qPCR.
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